

## ANTI-CLASTOGENIC EFFECTS OF *LAUNAEA TARAXACIFOLIA* LEAF EXTRACT ON CISPLATIN-INDUCED MICRONUCLEI IN BONE MARROW ERYTHROCYTES

Adejuwon S.A.<sup>1\*</sup>, Aina O. O.<sup>2</sup>, Femi-Akinlosotu O.M<sup>1</sup> and Omirinde J. O.<sup>2</sup>

<sup>1</sup>Department of Anatomy, College of Medicine, University of Ibadan, Ibadan, Nigeria.

<sup>2</sup>Department of Veterinary Anatomy, University of Ibadan, Ibadan, Nigeria.

**Email:** [yemade60@yahoo.com](mailto:yemade60@yahoo.com)

(Received on date: 19<sup>th</sup> November, 2013

Date of Acceptance: 5<sup>th</sup> January, 2014)

### ABSTRACT

This study investigates the anti-genotoxic potential of *Launaeataraxacifolia* (LT) aqueous leaf extract on cisplatin-induced micronuclei in bone marrow erythrocytes of Wistar rats. Thirty rats were randomly divided into 6 groups (I-VI) of 5 rats each. Groups III and IV were treated with 100 mg and 400 mg of LT via oral administration respectively for 21 days while Groups V and VI were similarly treated and then exposed to intraperitoneal (ip) administration of 10 mg/kg body wt cisplatin on the 21<sup>st</sup> day. Group II was only administered ip 10 mg/kg body wt cisplatin on day 21 and Group I which serves as control received water and food. The frequency of micronuclei polychromatic erythrocytes (MNPCEs) in exclusively cisplatin exposed Group II rats was significantly ( $p < 0.001$ ) higher when compared to control. The cytoprotective index (PCE: NCE) was also reduced in Group II rats while the PCE/NCE ratio increased significantly ( $P < 0.05$ ) in Group V and VI compared to group II rats. *Launaeataraxacifolia* leaf extract protects against cisplatin-induced genotoxic effect in bone marrow erythrocytes of rats.

**Keywords:** *Launaeataraxacifolia*, cisplatin, genotoxic, erythrocytes and rats

---

**Number of Figures: 3**

**Number of References: 20**

---

## INTRODUCTION

Cisplatin (cis-diamminedichloroplatinum, or cis-DDP) is a widely used chemotherapeutic drugs against a wide variety of animal tumors and human cancers (Calabresi and Parks, 1985). Parenrally administered, Cisplatin undergoes intracellular hydrolysis and form cytotoxic complexes with either DNA; RNA; sulphur-containing enzymes and mitochondria. The results of these interactions are DNA damage, mutagenesis, carcinogenesis, or apoptotic cell death (Krishnaswamy and Dewey, 1993). Its toxic side effects particularly target highly meristematic tissues of bone marrow, gastrointestinal mucosa etc with the clinical consequence of severe nausea, vomiting and myelo supression (Guneriet al., 2001; Rudrama et al., 2010). The generation of free radicals is thought to be an important mechanism in the development of these cisplatin-induced toxicities (Baligaet al., 1998; Weijlet al., 1997).

*Launaeataraxacifolia* also known as wild lettuce belongs to the family Asteraceae. The leaf is of high nutritional and medicinal values among inhabitants of SouthWestern Nigeria in West Africa where it is called *efoyanrin* (Adebisi, 2000). *Launaeataraxacifolia* is nutritionally rich in vitamins, minerals, proteins, essential fatty acids, fibre contents and flavonoids (Larson, 1988; Adinortey et al., 2012; Dickson et al., 2012; Gbadamosi et al., 2012). Despite a plethora of research works confirming phyto-antioxidants particularly polyphenols, flavonoids and phenolic acids as having chemopreventive activities (Grzegorzcyk et al., 2007), there is no published research

work on the protective roles of *L. taraxacifolia* against cisplatin induced micronuclei. This study then seeks to investigate this possibility. The results obtained may form the basis for the use of *Launaeataraxacifolia* as an ameliorating agent for cisplatin-induced toxicities.

## MATERIAL AND METHODS

### Collection and Authentication of Plant Material

The fresh leaves of *Launaeataraxifolia* were harvested from the flower beds around Faculty of Basic Medical Sciences, University of Ibadan, Nigeria and authenticated by Prof. A.E Ayodele of the herbarium at the Department of Botany, University of Ibadan with voucher number UIH-22370.

### Plant Extract preparation

The leaves (400 grams) were air-dried for 4 days, granulated and soaked in 2litres of distilled water heated at a sustained temperature of 60°C for 24 hours after which they were filtered using filter papers. The filtrate was concentrated using a rotary evaporator to give 13.76g residue, a yield of 3.44%. The administered dose was then calculated per kilogram body weight of the rats.

### Chemicals

The Cisplatin used was manufactured by Korea United Pharm. Inc. (Naojang, Chungnam, Korea) and procured from Kunle Ara pharmacy, a registered pharmaceuticals retail company. All other reagents were of analytic grade.

### Animal Protocol

Adult male Wistar rats weighing between 200 and 210 g, obtained from the Experimental Animal Unit of Faculty of Veterinary medicine, University of Ibadan, Nigeria, were housed in well-ventilated plastic cages, provided with rat pellets and water ad libitum. All the experimental animals were given humane care according to criteria provided in the "Guide for the Care and Use of Laboratory Animals" of the National Academy of Science published by the National Institutes of Health. The ethical regulations of the *University of Ibadan Ethical Committee for the protection of animal welfare during experiments* were strictly followed.

### Experimental design

Thirty healthy adult male Wistar rats were randomly divided to six groups of five rats each as follows:

- I. **Control:** received saline (5 ml/kg body weight) and water (5 ml/kg body weight) intraperitoneally.
- II. **Cisplatin(CIS):** were given a single dose of cisplatin (CIS) intraperitoneally at 10 mg/kg body wt. on the 21<sup>st</sup> day
- III. ***Launeataraxacifolia* (LT) 100mg:** given orally administered 100 mg of *Launeataraxacifolia* for 21 days.
- IV. **IV.LT 400mg:** were given orally administered 400 mg of *Launeataraxacifolia* for 21 days.
- V. **V.LT 100mg + CIS:** orally received 100 mg of *Launeataraxacifolia* for 21 days

plus single dose of 10 mg/kg body wt. of cisplatin intra peritoneally on the 21<sup>st</sup> day.


- VI. **LT 400mg + CIS:** were given 400 mg of *Launeataraxacifolia* for 21 days plus single dose of 10 mg/kg body wt. of cisplatin intraperitoneally on the 21<sup>st</sup> day. The rats were sacrificed by cervical dislocation on the 5<sup>th</sup> day after the administration of CIS and femoral bone was dissected out for the evaluation of micronuclei polychromatic erythrocytes (MNPCE) variations in bone marrow.

### Micronucleus assay


Bone marrow cells within femurs were flushed with 1ml of foetal bovine serum into a centrifuge tube, the suspension was centrifuged at 2200 rpm for 10 min, the supernatant was discarded and smears were prepared from the sediments on glass slides. The air-dried slides were fixed in methanol and stained with May-Grünwald and Giemsa. A total of 2000 polychromatic erythrocytes (PCEs) and normochromatic erythrocytes (NCE) were screened per animal for scoring the frequency of PCEs containing micronuclei and the ratio of PCEs to NCE was also determined.

### Statistical Analysis


The data obtained were analyzed using one-way analysis of variance (ANOVA) and the groups were compared using Turkey post hoc test for multiple comparisons. The level of significance was  $p < 0.05$ . While the results were expressed as group mean  $\pm$  standard error of mean (SEM).



**Fig 1:** The presence of micronucleus (white arrow) in cisplatin-treated animals



**Fig2:** The absence of micronucleus in *Launearaxacifolia*-treated rats.



**Fig 3:** Effect of aqueous extract of *Launearaxacifolia* on the frequency of MNPCEs and the PCE/NCE ratio in cisplatin treated rats. Bars with different letters are significantly different; p-values:  $a < 0.001$ ,  $b < 0.01$ -CIS compared with normal control;  $c < 0.05$ ,  $d < 0.01$ ,  $e < 0.05$  - experimental groups compared with CIS

## RESULT AND DISCUSSION

The MNPCEs frequency in figure 3 increased significantly ( $p < 0.001$ ) with concomitant decreased PCEs to NCEs ratio (an index of cyto protection) in cisplatin exposed Group II rats compared to control group. This data shows that cisplatin is genotoxic and this further corroborates its widely reported genotoxic property (Barbara et al., 1996; Giri et al., 1998). The latter has been attributed to DNA damage and successive DNA fragmentation, chromosomal breaks, and micronucleus formation causing genomic instability and eventually ends in mutagenesis, carcinogenesis, or apoptotic cell death. Pretreatment with 100 and 400 mg of *L. taraxacifolia* in Group V and VI significantly ( $p < 0.05$ ;  $p < 0.01$  respectively) reduced the frequency of MNPCE and increased significantly ( $p < 0.05$ ) the PCE/NCE ratio in a dose dependent fashion relative to cisplatin exposed Group II rats (Figure 3). These observations are in consonance with documentation on the beneficial effect of natural compounds in medicinal and dietary plants in reducing micronuclei formation and improving cyto-protective index as previously reported for *Murraya Koenigi* (Rudrama et al., 2010), *Cyamopsistetragonoloba* (Yadav et al., 2013) and *Salvia officinalis* leaves (Alkan et al., 2011).

## CONCLUSION

This study shows that *Launeataraxacifolia* leaf extract protect against cisplatin- induced genotoxic effect in bone marrow erythrocytes of rats. *Launeataraxacifolia* supplementation is therefore strongly recommended before cancer treatment.

## ACKNOWLEDGEMENT

The authors acknowledge the assistance of Prof Olaleye, Drs. G. Odaibo and Adeniyi of the Department of Virology, College of Medicine, and University of Ibadan, Nigeria in the procurement of foetal bovine serum used for this study.

## REFERENCES

**Adebisi AA.** Population of Neglected Indigenous Leafy Vegetables among the Yoruba tribe of South West Nigeria. CERNARD Development Series 06 CERNARD, Ibadan, Nigeria, 2000.

**Adinortey MB, Sarfo JK, Quayson ET, Weremfo A, Adinortey CA, Ekloh W, Ocran J.,** Phytochemical screening, proximate and mineral composition of *Launaeataraxacifolia* leaves. *Res. J. Med. Plants* 2: 171-179,2012

**Alkan FU, Gursel FE, Ates A, Ozyurek M, Guclu K, Altun M.** Protective effects of *Salvia officinalis* extract against cyclophosphamide-induced genotoxicity and oxidative stress in rats. *Turk. J. Vet. Anim. Sci* 36(6): 646-654,2012

**Baliga R, Zhang Z, Baliga M, Ueda N, Shah S.V.** In vitro and in-vivo evidence suggesting a role for iron in cisplatin induced nephrotoxicity. *Kidney Int.* 53: 394-401, 1998.

**Barbara JS, Sanderson R, Ferguson L, William AD.** Mutagenic and carcinogenic properties of platinum-based anticancer-70, drugs. *Mutagenicity of Anticancer Drugs.*1996; 355(1-2): 59.

**Calabresi P and Parks RE.** Antiproliferative agents and drugs used for immunosuppression. In: Goodman and Gilman's the Pharmacological basis of Therapeutics. 1985; 7th Ed., pp.1247-1307, Macmillan, New York.

**Dickson RA, Annan K, Fleischer TC, Amponsah IK, Nsiah K, Oteng JA.** Phytochemical Investigations and Nutritive Potential of Eight Selected Plants from Ghana. *Journal of Pharmacy and Nutrition Sciences*, 2012, 2, 172-177.

**Gbadamosi IT, Alia AE, Okolosi O.** In-vitro antimicrobial activities and nutritional assessment of roots of ten Nigerian vegetables. *New York Science Journal.*2012; 5(12).

**Geetha KY, Rudrama DK.** Evaluation of cypermethrin for mutagenicity in somatic and germ cells of mice. 1992. *Trends in Life Sciences*, 7(2), P 99-104.

**Giri A, Khunriam D, Prasad SB.** Cell mediated protection on cisplatin induced mutagenicity in mice. *Mutat Res.*, 1998; 3.421(2): 139-48.

**Grzegorzcyk I, Matkowski A, Wysokinska H.** Antioxidant activity of extracts from in vitro cultures of *Salvia officinalis*L. *Food Chem.*, 2007; 104: 536-541.

**Guneri EA, Serbetcioglu B, Ikiz AO, Guneri A, Ceryan TE.** OAE monitoring of cisplatin-induced ototoxicity in guinea pigs: The protective effect of vitamin B treatment. *AurisNasus Larynx* 2001; 28:9-14.

**Krishnaswamy G, Dewey WC.** Cisplatin induced cell killing and chromosomal

aberrations in CHO cells: treated during G1 or S phase. *Mutat. Res.* 1993;293:161-72.

**Kusum LC, Rudrama DK.** Cyto genetics Effects of Adriamycin in Bone Marrow Cells of Swiss Albino mice, 2010. *Bioscan*, 5(2); 317-320.

**Larson RA.** The antioxidants of higher plants. *Phytochemistry.* 1988; 27(4): 969-978.

**Manohar Reddy G. and Rudrama Devi K.** Mutagenicity of antihelmintic drugs in mammal 1. Effect of pyrantelpamoate on somatic cells, *Cell and Chromosome Research*, 13(3), P 21-23,1990

**Rudrama DK, Koushik A, Reddy VK.** Dose response relationship for cisplatin induced micronuclei in bone marrow erythrocytes of swiss albino mice, *BioScan* 5(4): 567-569,2010

**Rudrama DK, Reddy PP.** Evaluation of Metepa for Cytogenetic Effects Is Swiss Albino Mice, *Cell and Chromosome Research*, 9(2): 39-41,1986

**Weijl NI, Cleton FJ, Osanto S.** Free radicals and antioxidants in chemotherapy-induced toxicity. *CancerTreat.Rev.* 23: 209-240 (1997).

**Yadav S, Sahu P, Chaurasiya A.** A. Role of *cyamopsistetragonoloba* against cisplatin Induced genotoxicity: analysis of micronucleus and Chromosome aberrations *in vivo.* *J.Bio.Innov.*;2(4),pp:184-193,2013

